Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $31.25 Consensus Price Target from Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has been given an average recommendation of “Buy” by the five analysts that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $33.00.

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 target price on shares of Aardvark Therapeutics in a report on Tuesday, April 1st. HC Wainwright started coverage on shares of Aardvark Therapeutics in a research report on Monday, June 30th. They set a “buy” rating and a $40.00 price target on the stock. Royal Bank Of Canada lowered their price target on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an “overweight” rating and a $29.00 price target on the stock. Finally, Wall Street Zen cut shares of Aardvark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Decheng Capital LLC acquired a new position in Aardvark Therapeutics in the first quarter valued at about $29,419,000. Cormorant Asset Management LP acquired a new position in Aardvark Therapeutics in the first quarter valued at about $6,009,000. Braidwell LP acquired a new position in Aardvark Therapeutics in the first quarter valued at about $3,755,000. Adage Capital Partners GP L.L.C. acquired a new position in Aardvark Therapeutics in the first quarter valued at about $1,878,000. Finally, Goldman Sachs Group Inc. acquired a new position in Aardvark Therapeutics in the first quarter valued at about $153,000.

Aardvark Therapeutics Stock Up 3.0%

Aardvark Therapeutics stock opened at $13.92 on Monday. Aardvark Therapeutics has a 52-week low of $4.88 and a 52-week high of $19.58. The business’s fifty day simple moving average is $11.51.

Aardvark Therapeutics (NASDAQ:AARD) last released its earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01).

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.